The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response.

2.50
Hdl Handle:
http://hdl.handle.net/10033/135059
Title:
The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response.
Authors:
Knothe, S; Mutschler, V; Rochlitzer, S; Winkler, C; Ebensen, T; Guzman, C A; Hohlfeld, J; Braun, A; Muller, M
Abstract:
One experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid αgalactosylceramide. For a first evaluation of the immunomodulatory potential of αGalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, αGalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention.
Affiliation:
Fraunhofer Institute for Toxicology and Experimental Medicine, Department of Immunology, Allergology and Immunotoxicology, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany.
Citation:
The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response. 2011, 29 (25):4249-55 Vaccine
Journal:
Vaccine
Issue Date:
6-Jun-2011
URI:
http://hdl.handle.net/10033/135059
DOI:
10.1016/j.vaccine.2011.03.068
PubMed ID:
21463684
Type:
Article
Language:
en
ISSN:
1873-2518
Appears in Collections:
publications of the research group vaccinology and applied microbiology (VAC)

Full metadata record

DC FieldValue Language
dc.contributor.authorKnothe, Sen
dc.contributor.authorMutschler, Ven
dc.contributor.authorRochlitzer, Sen
dc.contributor.authorWinkler, Cen
dc.contributor.authorEbensen, Ten
dc.contributor.authorGuzman, C Aen
dc.contributor.authorHohlfeld, Jen
dc.contributor.authorBraun, Aen
dc.contributor.authorMuller, Men
dc.date.accessioned2011-07-01T13:53:14Z-
dc.date.available2011-07-01T13:53:14Z-
dc.date.issued2011-06-06-
dc.identifier.citationThe NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response. 2011, 29 (25):4249-55 Vaccineen
dc.identifier.issn1873-2518-
dc.identifier.pmid21463684-
dc.identifier.doi10.1016/j.vaccine.2011.03.068-
dc.identifier.urihttp://hdl.handle.net/10033/135059-
dc.description.abstractOne experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid αgalactosylceramide. For a first evaluation of the immunomodulatory potential of αGalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, αGalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention.en
dc.language.isoenen
dc.titleThe NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response.en
dc.typeArticleen
dc.contributor.departmentFraunhofer Institute for Toxicology and Experimental Medicine, Department of Immunology, Allergology and Immunotoxicology, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany.en
dc.identifier.journalVaccineen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.